J

Johnson & Johnson

Makes prescription drugs and medical devices

Technical Product Manager - Vision Plan

Full-TimeUpdated on 10/23/2026Deadline 10/31/26
$102k - $175.9k
Senior, Expert
Bachelor's
Raritan, NJ, USA+1 moreMore locations: Jacksonville, FL, USA
RemoteFully remote; role may be based in Jacksonville, Florida, Raritan, New Jersey, or remote.
ProductTechnical Product Management

About the job

Requirements
  • A bachelor's degree in Business Administration, Supply Chain Management, Computer Science, or a field relevant to the job is required.
  • At least 8 years of experience in technical product management, solution delivery, business technology, or supply chain planning systems is required.
  • Hands-on experience with OMP Plus planning software or similar advanced planning applications, such as Kinaxis, Blue Yonder, SAP IBP/APO, o9, Oracle SCM Planning, or equivalent, is required.
  • Demonstrated understanding of end-to-end supply chain planning processes, including demand planning, supply planning, inventory planning, capacity planning, and scenario-based planning, is required.
  • Proficiency working with agile and scrum methodologies and tools, including Jira, Confluence, or similar platforms, is required.
  • Strong knowledge of systems product development, software delivery lifecycle practices, change management, and technology governance in a regulated industry is required.
  • A track record of effectively working with cross-functional business, technology, vendor, and global teams is required.
  • The ability to use data, user feedback, technical insight, and business value to guide product decisions and prioritization is required.
  • The ability to manage ambiguity, drive issues to resolution, follow through on commitments, and remain accountable for business and technology outcomes is required.
  • The ability to translate technical concepts into clear messages for business users, senior leaders, technical teams, and external partners is required.
  • Excellent English verbal and written communication skills, including formal presentations, executive summaries, release communications, incident updates, and technical documentation, are required.
  • Experience leading or influencing large, culturally diverse, global teams is required.
Responsibilities
  • Serve as a Technical Product Manager for OMP Plus planning capabilities, providing technical guidance across planning processes, integrations, master data dependencies, configuration, testing, release readiness, and production support.
  • Develop a deep understanding of customer needs, supply chain planning processes, market trends, and emerging capabilities in advanced planning and optimization technologies.
  • Collaborate with business planning leaders, architects, engineers, vendors, and cross-functional teams to define product requirements, prioritize features, manage dependencies, and shape the product roadmap.
  • Lead development and execution of the Vision Plan product strategy, ensuring effective implementation, adoption, and value realization across business and technology stakeholders.
  • Drive product development and enhancements through the full product lifecycle, from business problem definition and solution design through deployment, adoption, support, and continuous improvement using agile methodology.
  • Work with engineering, design, architecture, and Technology Services teams to ensure solutions meet quality, performance, security, compliance, and maintainability expectations while continually improving portfolio effectiveness and efficiency.
  • Partner with Business Product Owners, leaders of other product groups, JJTS, external vendors, and enterprise architecture teams on solution assessments, integration design, technical decisions, and roadmap alignment.
  • Monitor product performance, production stability, user experience, and business outcomes; identify improvement opportunities and drive corrective actions to enhance stakeholder satisfaction and business success.
  • Co-manage budget, provide delivery estimates, and remain accountable for total cost of ownership optimization across Plan products and services.
  • Track product development and deployment progress, manage risks and dependencies, provide status updates to business and technology leaders, and ensure predictable delivery of solutions.
  • Translate complex technical topics into business-facing communications, including roadmap updates, release notes, issue summaries, impact assessments, executive updates, and stakeholder presentations.
  • Drive issues to resolution, follow through on commitments, escalate risks appropriately, and ensure accountability across delivery, operations, and adoption.
Desired Qualifications
  • Experience with SAP ECC or S/4HANA integration touchpoints, including planning master data, material master, customer/location data, IDocs, interfaces, and integration troubleshooting.
  • Experience supporting production operations, incident management, root cause analysis, change management, release deployment, and continuous improvement processes.
  • Familiarity with data flows, system integrations, SQL, APIs, middleware, job scheduling, cloud-based application environments, or related technical concepts.
  • Experience supporting regulated environments, validated systems, GxP/compliance-driven technology delivery, or quality-controlled release processes.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.